X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Glenmark Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs MYLAN (US) - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GLENMARK PHARMA   MYLAN
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
MYLAN
Dec-14
GLENMARK PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs9934,042-   
Low Rs7292,848-   
Sales per share (Unadj.) Rs325.51,383.8-  
Earnings per share (Unadj.) Rs39.3166.7-  
Cash flow per share (Unadj.) Rs48.7268.3-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs159.2687.9-  
Shares outstanding (eoy) m282.17378.37-   
Bonus/Rights/Conversions ESOPOI-  
Price / Sales ratio x2.62.5 106.2%   
Avg P/E ratio x21.920.7 106.0%  
P/CF ratio (eoy) x17.712.8 137.8%  
Price / Book Value ratio x5.45.0 108.0%  
Dividend payout %5.10-   
Avg Mkt Cap Rs m242,9911,303,581 18.6%   
No. of employees `00013.025.0 51.9%   
Total wages/salary Rs m16,4080-   
Avg. sales/employee Rs Th7,083.920,942.8 33.8%   
Avg. wages/employee Rs Th1,265.40-   
Avg. net profit/employee Rs Th855.12,522.9 33.9%   
INCOME DATA
Net Sales Rs m91,857523,570 17.5%  
Other income Rs m374-3,052 -12.2%   
Total revenues Rs m92,230520,519 17.7%   
Gross profit Rs m20,367130,214 15.6%  
Depreciation Rs m2,64438,454 6.9%   
Interest Rs m2,37322,584 10.5%   
Profit before tax Rs m15,72466,125 23.8%   
Minority Interest Rs m0-271 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,8272,781 137.6%   
Profit after tax Rs m11,08863,073 17.6%  
Gross profit margin %22.224.9 89.2%  
Effective tax rate %24.34.2 578.8%   
Net profit margin %12.112.0 100.2%  
BALANCE SHEET DATA
Current assets Rs m68,746460,288 14.9%   
Current liabilities Rs m27,027359,853 7.5%   
Net working cap to sales %45.419.2 236.8%  
Current ratio x2.51.3 198.9%  
Inventory Days Days8578 108.9%  
Debtors Days Days96107 89.1%  
Net fixed assets Rs m24,132121,127 19.9%   
Share capital Rs m28218,515 1.5%   
"Free" reserves Rs m44,6430-   
Net worth Rs m44,925260,266 17.3%   
Long term debt Rs m45,363388,812 11.7%   
Total assets Rs m117,6391,048,328 11.2%  
Interest coverage x7.63.9 194.1%   
Debt to equity ratio x1.01.5 67.6%  
Sales to assets ratio x0.80.5 156.3%   
Return on assets %11.48.2 140.0%  
Return on equity %24.724.2 101.8%  
Return on capital %19.113.6 140.5%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m48,0680-   
CASH FLOW
From Operations Rs m6,57468,824 9.6%  
From Investments Rs m-7,124-54,276 13.1%  
From Financial Activity Rs m5,432-18,135 -30.0%  
Net Cashflow Rs m1,992-3,588 -55.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 67.82 Rs / USD

Compare GLENMARK PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare GLENMARK PHARMA With: SUVEN LIFE  PANACEA BIOTECH  J.B.CHEMICALS  DR. REDDYS LAB  WOCKHARDT LTD.  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views On News

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6% (Quarterly Result Update)

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jun 22, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS